| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6096331 | BRISTOL-MYERS | Methods and compositions useful for administration of chemotherapeutic agents |
Feb, 2013
(11 years ago) | |
| US6753006 | BRISTOL-MYERS | Paclitaxel-containing formulations |
Feb, 2013
(11 years ago) | |
| US5439686 | BRISTOL-MYERS | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
Feb, 2013
(11 years ago) | |
| US6506405 | BRISTOL-MYERS | Methods and formulations of cremophor-free taxanes |
Feb, 2013
(11 years ago) | |
| US6537579 | BRISTOL-MYERS | Compositions and methods for administration of pharmacologically active compounds |
Feb, 2013
(11 years ago) | |
| US6749868 | BRISTOL-MYERS | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
Feb, 2013
(11 years ago) | |
| US5498421 | BRISTOL-MYERS | Composition useful for in vivo delivery of biologics and methods employing same |
Mar, 2013
(11 years ago) | |
| USRE41884 | BRISTOL-MYERS | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
Aug, 2016
(7 years ago) | |
| US8853260 | BRISTOL-MYERS | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
Oct, 2020
(3 years ago) | |
|
US8853260 (Pediatric) | BRISTOL-MYERS | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
Apr, 2021
(3 years ago) | |
| US8314156 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(4 months ago) | |
| US7923536 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(4 months ago) | |
| US8138229 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(4 months ago) | |
|
US8314156 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(a month from now) | |
|
US7923536 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(a month from now) | |
|
US8138229 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(a month from now) | |
| US7820788 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Oct, 2024
(6 months from now) | |
|
US7820788 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Apr, 2025
(a year from now) | |
| US8268348 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(1 year, 9 months from now) | |
| US7758891 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(1 year, 9 months from now) | |
| US9101543 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(1 year, 9 months from now) | |
| US8034375 | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US9101543 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US7758891 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US8268348 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(2 years from now) | |
|
US8034375 (Pediatric) | BRISTOL-MYERS | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2027
(2 years from now) | |
| US9393318 | BRISTOL-MYERS | Methods of treating cancer |
Mar, 2032
(7 years from now) | |
| US9597409 | BRISTOL-MYERS | Methods of treating cancer |
Mar, 2032
(7 years from now) | |
|
US9393318 (Pediatric) | BRISTOL-MYERS | Methods of treating cancer |
Sep, 2032
(8 years from now) | |
|
US9597409 (Pediatric) | BRISTOL-MYERS | Methods of treating cancer |
Sep, 2032
(8 years from now) | |
| US9511046 | BRISTOL-MYERS | Methods of treating pancreatic cancer |
Jan, 2034
(9 years from now) | |
|
US9511046 (Pediatric) | BRISTOL-MYERS | Methods of treating pancreatic cancer |
Jul, 2034
(10 years from now) | |
Abraxane is owned by Bristol-Myers.
Abraxane contains Paclitaxel.
Abraxane has a total of 32 drug patents out of which 13 drug patents have expired.
Expired drug patents of Abraxane are:
- US6096331
- US6753006
- US5439686
- US6506405
- US6537579
- US6749868
- US5498421
- USRE41884
- US8853260
- US8853260*PED
- US8314156
- US7923536
- US8138229
Abraxane was authorised for market use on 07 January, 2005.
Abraxane is available in powder;intravenous dosage forms.
Abraxane can be used as treatment of breast cancer, method for treatment of tumors by administering paclitaxel at a dose in the range of about 30mg/meter square to about 100mg/meter square in a pharmaceutically acceptable formulation that does not contain cremophor, method of treatment of cancer by administering particles of paclitaxel that have a protein coating, treatment of lung cancer, method for delivery of a biologic (including antineoplastic agents) by administering to a patient an effective amount of a biologic as a solid or liquid with a polymeric biocompatible material, treatment of pancreatic cancer.
The generics of Abraxane are possible to be released after 12 July, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 06, 2023 |
| M(M-14) | Dec 06, 2022 |
| New Indication(I-676) | Sep 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Sep 06, 2020 |
| Orphan Drug Exclusivity(ODE-52) | Sep 06, 2020 |
| New Indication(I-658) | Oct 11, 2015 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Method for treatment of tumors by administering paclitaxel at a dose in the range of about 30mg/meter square to about 100mg/meter square in a pharmaceutically acceptable formulation that does not cont...
Dosage: POWDER;INTRAVENOUS
ABRAXANE family patents
